ClinicalTrials.gg
CompletedNCT00598650Updated Sep 3, 2014Results posted

A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies

A Phase 2 interventional study of E2020 in Dementia With Lewy Bodies (DLB), sponsored by Eisai Co., Ltd.. Completed. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2014-09-03.

Sponsored by Eisai Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and efficacy of E2020 in patients with Dementia with Lewy Bodies (DLB).

02

Conditions studied

  • Dementia With Lewy Bodies (DLB)

Keywords

  • Lewy Body Disease
  • Dementia
  • Clinical Trial
  • Phase II
  • E2020
  • donepezil hydrochloride
03

In context

Lewy Body Disease

239 studies on the registry are indexed under Lewy Body Disease; 88 are open to participants now.

This study's enrollment of 160 is above the median of 86 across 152 interventional studies indexed under Lewy Body Disease.

Browse Lewy Body Disease studies →

Lead sponsor

Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients diagnosed as probable Dementia with Lewy Bodies (DLB) according to the diagnostic criteria for DLB.
  2. Patients who have completed Phase II double-blind study (E2020-J081-431).
  3. Patients having caregivers who submit written consent for cooperative involvement in this study, can routinely stay with patients 3 days a week (at least 4 hours a day), provide patients' information necessary for this study, assist treatment compliance and escort their patients on required visits to study institution.

Exclusion criteria

Exclusion criteria:

  1. Patients with a complication of serious neuropsychiatric disease(s) such as stroke, brain tumor, schizophrenia, epilepsy, normal pressure hydrocephalus, mental retardation, brain trauma with unconsciousness, and/or who underwent brain surgery causing unsolved deficiency.
  2. Patients with severe complication of cardiovascular, hepatic, renal, hematological, or other diseases unable to secure the safety.
  3. Pregnant or lactating women, or women who are willing to become pregnant no later than 1 month after the scheduled study completion.
  4. Patients with severe extrapyramidal disorders (Hoehn and Yahr staging score is greater than IV).
  5. Patients whose systolic blood pressure is less than 90 mmHg or pulse rate is less than 50 beats/min.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    1

    Drug: E2020

Interventions

  • DrugE2020

    Dosage and administration: Patients will receive oral administration of 1 tablet of 3 mg (E2020) from Day 1 to Day 14 of treatment period, 1 tablet of 5 mg (E2020) from Day 15 onwards once daily after breakfast.

    Also known as: Aricept

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mini-mental State Examination (MMSE) Total

    MMSE measured general cognitive functioning: orientation, memory, attention, calculation, language, visuospatial functions. Total score derived from sub-scores; total ranged from 0 - 30, where a higher score indicated better cognitive state.

    Time frame: Baseline, Week 52, and Week 52 LOCF

  2. Change From Baseline in Neuropsychiatric Inventory (NPI) Score of Psychiatric Symptoms

    NPI measured 10 different domains of psychiatric symptoms including delusion and hallucination. Each domain is scored for: present or absent, frequency, and severity. The score derived from sub-scores; total ranged from "0" to "120," higher score indicated worse neuropsychiatric outcomes.

    Time frame: Baseline, Week 52, and Week 52 LOCF

07

Results

Posted Sep 3, 2014

Participant flow

Participant flow — Overall Study
MilestoneE2020
Started108
Completed81
Not completed27
Withdrew: Withdrawal by subject3
Withdrew: Adverse event18
Withdrew: No treatment for 3 weeks1
Withdrew: Not eligible1
Withdrew: Prohibited concomitant medication2
Withdrew: Physician decision2

Outcome measures

PrimaryChange From Baseline in Mini-mental State Examination (MMSE) Total

MMSE measured general cognitive functioning: orientation, memory, attention, calculation, language, visuospatial functions. Total score derived from sub-scores; total ranged from 0 - 30, where a higher score indicated better cognitive state.

Time frame:
Baseline, Week 52, and Week 52 LOCF
Reported as:
Mean · Score on a Scale
Change From Baseline in Mini-mental State Examination (MMSE) Total
Score on a ScaleE2020Placebo/E2020
Baseline20.9 ± 5.118.6 ± 4.7
Week 520.3 ± 3.72 ± 4.4
Week 52 LOCF0.2 ± 3.51.7 ± 4.4
PrimaryChange From Baseline in Neuropsychiatric Inventory (NPI) Score of Psychiatric Symptoms

NPI measured 10 different domains of psychiatric symptoms including delusion and hallucination. Each domain is scored for: present or absent, frequency, and severity. The score derived from sub-scores; total ranged from "0" to "120," higher score indicated worse neuropsychiatric outcomes.

Time frame:
Baseline, Week 52, and Week 52 LOCF
Reported as:
Mean · Score on a Scale
Change From Baseline in Neuropsychiatric Inventory (NPI) Score of Psychiatric Symptoms
Score on a ScaleE2020Placebo/E2020
Baseline13.1 ± 16.817.8 ± 8.2
Week 52-1.9 ± 9.8-4.1 ± 10.1
Week 52 LOCF-0.7 ± 11.1-4.3 ± 9.7

Adverse events

Collected over Up to 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
E2020—8/108 (7.4%)53/108 (49.1%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventE2020
Compression fractureInjury, poisoning and procedural complications3/108
PneumoniaInfections and infestations3/108
DehydrationMetabolism and nutrition disorders2/108
Psychiatric symptomPsychiatric disorders1/108
DizzinessNervous system disorders1/108
PoriomaniaPsychiatric disorders1/108
Cervix carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/108
Cerebellar infarctionNervous system disorders1/108
Bile duct cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/108
Hepatic function abnormalHepatobiliary disorders1/108
Most frequent other events
Showing 10 of 13
Most frequent other events
EventE2020
Blood creatine phosphokinase increasedInvestigations12/108
ContusionInjury, poisoning and procedural complications12/108
NasopharyngitisInfections and infestations11/108
Blood pressure increasedInvestigations11/108
FallInjury, poisoning and procedural complications11/108
DiarrhoeaGastrointestinal disorders10/108
ParkinsonismNervous system disorders8/108
ConstipationGastrointestinal disorders8/108
Blood urine presentInvestigations7/108
Protein urine presentInvestigations7/108

Baseline characteristics

Age, Continuous
Age, Continuous(Years)E2020
Mean78.9 ± 5.7
Sex: Female, Male
Sex: Female, Male(Participants)E2020
Female68
Male40
Weight
Weight(kg)E2020
Mean49 ± 9.24
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2008
First posted
Jan 22, 2008
Start
Feb 2008
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Results first posted
Sep 3, 2014
Last update
Sep 3, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00598650
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Jan 22, 2008
Start date
Feb 2008
Primary completion
Mar 2011
Completion
Mar 2011
Results posted
Sep 3, 2014
Last update
Sep 3, 2014

Study contacts

Itaru Arimoto
study director · New Product Development, Clinical Research Center, Eisai Co., Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion